Please login to the form below

Not currently logged in
Email:
Password:

Bayer sees increase in Q1 sales

Bayer has reported a five per cent increase in first-quarter sales of pharmaceuticals to €2.6bn compared to 2008, for products such as Betaferon and Nexavar

Bayer has reported a five per cent increase in first-quarter sales of pharmaceuticals to €2.6bn compared to 2008, for products such as Betaferon and Nexavar. Sales for the company's HealthCare unit gained three per cent to €3.8bn.

Betaferon/Betaseron posted a 9.9 per cent sales increase to €301m over the comparable quarter, while Nexavar's revenue jumped 36 per cent to €137m. The German pharmaceutical and chemical company also reported that combined quarterly revenue from contraceptives YAZ, Yasmin and Yasminelle increased 7.4 per cent to €319m.

CEO Werner Wenning said "our pharmaceutical business saw pleasing growth overall" and added that Bayer's HealthCare unit "plans to achieve currency-adjusted growth rates ahead of the market average in all divisions" in 2009.

However, overall company profit decreased 44 per cent to €425m due to the impact of the global economic recession on other business segments such as plastics and adhesive chemicals. Quarterly group revenue was 7.5 per cent lower than the same period last year at €7.9bn.

30th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics